Meeting
2020 Gastrointestinal Cancers Symposium
The potential in artificial intelligence-driven radiomic signature to predict survival in patients with metastatic colorectal cancer treated with cetuximab-based therapy.
Authors
Laurent Dercle
Department of Radiology, Columbia University Medical Center; New York-Presbyterian Hospital, New York, NY
Laurent Dercle , Lin Lu , Lawrence Howard Schwartz , Min Qian , Sabine Tejpar , Peter Eggleton , Binsheng Zhao , Hubert Piessevaux
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Other
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 247)
Abstract #
247
Poster Bd #
M3
Abstract Disclosures
Similar Posters
![BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAF<sup>V600E</sup> mCRC.](https://d201v5jt9ylckg.cloudfront.net/199/11943/153243/153243_poster_pv.jpg)
First Author: Sanne Huijberts
Poster
2011 ASCO Annual Meeting
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS mutated tumors in the randomized German AIO study KRK-0306.
First Author: S. Stintzing
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
First Author: Atsushi Ishiguro
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang